Details

---

• MAL Registration Number: MAL16075031ACRZ

• Manufacturer: Novartis Pharma Stein AG, Switzerland

Content

• Active Ingredient: Letrozole 2.5 mg

• Excipients: Each tablet contains 61.5 mg of lactose (monohydrate).

• Formulation: Film-coated tablet, dark yellow, round, slightly biconvex with bevelled edges.

Indications

Femara 2.5mg is indicated for the treatment of breast cancer in postmenopausal women:

• Adjuvant Treatment: For hormone receptor-positive early breast cancer.

• Extended Adjuvant Treatment: Following 5 years of tamoxifen therapy.

• First-Line Treatment: For hormone-dependent advanced breast cancer.

• Treatment After Relapse: In women with natural or artificially induced postmenopausal status, previously treated with anti-oestrogens.

• Neo-Adjuvant Treatment: For hormone receptor-positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery is not indicated.

Instructions for Use

• Dosage: The recommended dose is 2.5 mg once daily.

• Administration: Take orally, with or without food.

• Missed Dose: If a dose is missed, take it as soon as remembered unless it's almost time for the next dose. Do not double the dose.

• Duration: Treatment should continue for 5 years or until tumor relapse occurs, whichever comes first.